Nektar Therapeutics Reports Positive Phase 2b Maintenance Data for Atopic Dermatitis Drug, Aligns with FDA for Phase 3
NKTR has more than doubled off its 52-week low of $6.48.
Summary
Nektar Therapeutics announced positive 36-week maintenance results for rezpegaldesleukin in moderate-to-severe atopic dermatitis, demonstrating durable efficacy and a favorable safety profile, and confirmed alignment with the FDA for planned Phase 3 trials starting in Q2 2026.
Key Events · Product Development and Regulatory · NKTR
-
Positive Phase 2b Maintenance Results
Rezpegaldesleukin demonstrated durable and deepening efficacy in moderate-to-severe atopic dermatitis over a 36-week maintenance period, with high rates of EASI-75, EASI-90, and vIGA-AD 0/1 responses.
-
Increased EASI-100 Response Rates
The 24 µg/kg monthly and quarterly dosing regimens showed a 2 to 5-fold increase in patients achieving complete skin clearance (EASI-100) by Week 52.
-
Favorable Safety Profile
The drug was well-tolerated with no new safety concerns identified during the maintenance period, and a low discontinuation rate due to adverse events (3.5%).
-
FDA Alignment for Phase 3
Nektar reached alignment with the FDA on the Phase 3 trial design, including a 24 µg/kg Q2W induction dose and co-primary endpoints of EASI-75 and an IGA-related endpoint.
Analysis · NKTR · Life Sciences
This 8-K filing is highly significant for Nektar Therapeutics as it provides strong positive clinical data for rezpegaldesleukin, its lead regulatory T-cell biologic for atopic dermatitis. The sustained efficacy and deepening of responses observed during the 36-week maintenance period, including a notable increase in EASI-100 response rates, suggest a compelling therapeutic profile. The consistent and favorable safety profile further de-risks the program. Crucially, the company has achieved alignment with the FDA on the Phase 3 trial design, which includes a clear path for induction and maintenance dosing regimens, and plans to initiate these pivotal trials in Q2 2026 with a target BLA filing in 2029. This progress significantly advances rezpegaldesleukin towards commercialization and validates its novel mechanism of action, positioning it as a potential best-in-class immune-modulator in a large market.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NKTR was trading at $42.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $754.1M. The 52-week trading range was $6.48 to $66.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.